These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38128180)

  • 41. Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer.
    Lu T; Tang J; Shrestha B; Heath BR; Hong L; Lei YL; Ljungman M; Neamati N
    Theranostics; 2020; 10(15):6959-6976. PubMed ID: 32550915
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Butein Inhibits Cell Growth by Blocking the IL-6/IL-6Rα Interaction in Human Ovarian Cancer and by Regulation of the IL-6/STAT3/FoxO3a Pathway.
    Park SA; Seo YJ; Kim LK; Kim HJ; Yoon KD; Heo TH
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047012
    [No Abstract]   [Full Text] [Related]  

  • 43. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
    Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
    Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Guizhi Fuling Wan, Chinese Herbal Medicine, Ameliorates Insulin Sensitivity in PCOS Model Rats With Insulin Resistance via Remodeling Intestinal Homeostasis.
    Zhu Y; Li Y; Liu M; Hu X; Zhu H
    Front Endocrinol (Lausanne); 2020; 11():575. PubMed ID: 32973686
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Add-on effect of Guizhi Fuling formula to mifepristone for endometriosis: A meta-analysis of randomized controlled trials.
    Meng W; Ta N; Wang F
    Medicine (Baltimore); 2019 Aug; 98(33):e16878. PubMed ID: 31415429
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
    Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
    J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reactive oxygen species promote ovarian cancer progression via the HIF-1α/LOX/E-cadherin pathway.
    Wang Y; Ma J; Shen H; Wang C; Sun Y; Howell SB; Lin X
    Oncol Rep; 2014 Nov; 32(5):2150-8. PubMed ID: 25174950
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fraxetin suppresses the proliferation, migration, and invasion of ovarian cancer cells by inhibiting the TLR4/STAT3 signaling pathway.
    Xu R; Ruan Y; Zhang L; Gu Y; Liu M
    Immunopharmacol Immunotoxicol; 2023 Jun; 45(3):287-294. PubMed ID: 36346016
    [TBL] [Abstract][Full Text] [Related]  

  • 49. m6A-modified circNFIX promotes ovarian cancer progression and immune escape via activating IL-6R/JAK1/STAT3 signaling by sponging miR-647.
    Wang R; Ye H; Yang B; Ao M; Yu X; Wu Y; Xi M; Hou M
    Int Immunopharmacol; 2023 Nov; 124(Pt A):110879. PubMed ID: 37713785
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NR1D1 suppressed the growth of ovarian cancer by abrogating the JAK/STAT3 signaling pathway.
    Wang H; Fu Y
    BMC Cancer; 2021 Jul; 21(1):871. PubMed ID: 34330232
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3.
    Selvendiran K; Bratasz A; Kuppusamy ML; Tazi MF; Rivera BK; Kuppusamy P
    Int J Cancer; 2009 Nov; 125(9):2198-204. PubMed ID: 19623660
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized double-blind trial comparing low dose and conventional dose of a modified traditional herbal formula Guizhi Fuling Wan in women with symptomatic uterine fibroids.
    Meng W; Lin WL; Yeung WF; Zhang Y; Ng EHY; Lee YPE; Zhang ZJ; Rong J; Lao L
    J Ethnopharmacol; 2022 Jan; 283():114676. PubMed ID: 34562564
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Study on the regulatory mechanism and experimental verification of icariin for the treatment of ovarian cancer based on network pharmacology.
    Wang S; Gao J; Li Q; Ming W; Fu Y; Song L; Qin J
    J Ethnopharmacol; 2020 Nov; 262():113189. PubMed ID: 32736044
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway.
    Chen M; Zeng J; Chen S; Li J; Wu H; Dong X; Lei Y; Zhi X; Yao L
    Aging (Albany NY); 2020 Jun; 12(11):10896-10911. PubMed ID: 32516133
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Novel Monoclonal Antibody Targeting Cancer-Specific Plectin Has Potent Antitumor Activity in Ovarian Cancer.
    Perez SM; Dimastromatteo J; Landen CN; Kelly KA
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571866
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fuling Granule, a Traditional Chinese Medicine Compound, Suppresses Cell Proliferation and TGFβ-Induced EMT in Ovarian Cancer.
    Tao F; Ruan S; Liu W; Wang L; Xiong Y; Shen M
    PLoS One; 2016; 11(12):e0168892. PubMed ID: 28036353
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of alpha6beta1 integrin.
    Colomiere M; Findlay J; Ackland L; Ahmed N
    Int J Biochem Cell Biol; 2009 May; 41(5):1034-45. PubMed ID: 18930836
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo.
    Zhang X; Liu P; Zhang B; Mao H; Shen L; Ma Y
    Int J Mol Med; 2013 Sep; 32(3):623-8. PubMed ID: 23828376
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Guizhi Fuling Formulation: A review on chemical constituents, quality control, pharmacokinetic studies, pharmacological properties, adverse reactions and clinical applications.
    Liu X; Chen L; Sun P; Zhan Z; Wang J
    J Ethnopharmacol; 2024 Jan; 319(Pt 2):117277. PubMed ID: 37802375
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Valtrate as a novel therapeutic agent exhibits potent anti-pancreatic cancer activity by inhibiting Stat3 signaling.
    Chen L; Feng D; Qian Y; Cheng X; Song H; Qian Y; Zhang X; Wu Y; Lv H; Liu Q; Cheng G; Yang B; Gu M
    Phytomedicine; 2021 May; 85():153537. PubMed ID: 33744595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.